Prurigo nodularis and pembrolizumab: A therapeutic challenge.

[1]  G. Fabbrocini,et al.  Bullous pemphigoid and nivolumab: Dermatologic management to support and continue oncologic therapy. , 2018, European journal of cancer.

[2]  V. Sibaud.  Dermatologic Reactions to Immune Checkpoint Inhibitors , 2018, American Journal of Clinical Dermatology.

[3]  S. Ständer,et al.  The pathogenesis of Prurigo nodularis – ‘Super‐Itch’ in exploration , 2016, European journal of pain.

[4]  J. Wolchok,et al.  Immune Checkpoint Blockade in Cancer Therapy. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Gadano,et al.  Efficacy of lidocaine in the treatment of pruritus in patients with chronic cholestatic liver diseases. , 2005, The American journal of medicine.

[6]  S. Ständer,et al.  Prurigo Nodularis Management. , 2016, Current problems in dermatology.